Biocon Receives Approval from Health Canada for Biosimilar Medicines Yesintek and Yesintek IV

Biocon Receives Approval from Health Canada for Biosimilar Medicines Yesintek and Yesintek IV

On October 23, 2023, Biocon Receives Approval from Health Canada for two important biosimilar medicines, Yesintek and Yesintek IV. This major milestone strengthens Biocon Ltd’s global presence through its subsidiary, Biocon Biologics Ltd. The approval lets the company sell these drugs in Canada, giving patients with chronic autoimmune diseases more affordable treatment options. Health Canada…

Keep Reading..